oral tirzepatide pills TABLETS Oral Tirzepatide vs Injection: Which

PMID: 35857644 (Tirzepatide vs semaglutide: How do they compare

these patients had more recent interactions, and therefore, may be less healthy than the general population receiving GLP-1s

It is suitable for multiple delivery formats, including capsules, sachets, and functional powder blends

, , GLP-1

doi: 10.1016/S0140-6736(18)32260-8 112 FrasJPDaviesMJRosenstockJPrez ManghiFCFernndez LandLBergmanBKet al

Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment